Advicenne
ALDVI.PAPhase 3Specialty pharmaceutical company focused on the development of pediatric friendly therapeutics for the treatment of orphan renal diseases and neurology.
Market Cap
$30.4M
Founded
2022
Focus
Small Molecules
ALDVI.PA · Stock Price
USD 1.813.29 (-64.48%)
Historical price data
About
Specialty pharmaceutical company focused on the development of pediatric friendly therapeutics for the treatment of orphan renal diseases and neurology.
Pipeline Snapshot
66 drugs in pipeline, 4 in Phase 3
| Drug | Indication | Stage |
|---|---|---|
| ADV7103 + Placebo | Distal Renal Tubular Acidosis | Phase 3 |
| ADV7103 | Acidosis, Renal Tubular | Phase 3 |
| ADV7103 + Standard of Care | Cystinuria | Phase 2/3 |
| ADV7103 + Placebo | Cystinuria | Phase 2/3 |
| Sulthiame | Epilepsy | Phase 1 |
Funding History
3Total raised: $65M
IPO$30MUndisclosedJul 20, 2017
Series B$25MUndisclosedMar 15, 2016
Series A$10MUndisclosedJun 15, 2014
Company Info
TypePublic
Founded2022
LocationNîmes, France
StagePhase 3
Contact
SIMILAR COMPANIES
4P-Pharma
Phase 2 · Lille
Patheon
Pre-clinical · Lyon
ABL Diagnostics
Pre-clinical · Strasbourg
Acticor Biotech
Pre-clinical · Paris
Adjuvatis
Pre-clinical · Lyon
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile